Applying Next-Generation Sequencing to Track HIV-1 Drug Resistance Mutations Circulating in Portugal
Viruses · 2024
DOI: 10.3390/v16040622 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Victor Pimentel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Global Health and Tropical Medicine (GHTM), Associate Laboratory in Translation and Innovation Towards Global Health (LA-REAL), Instituto de Higiene …. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FCT in the Scopus of INTEGRIV project, FCT MARVEL, Calouste Gulbenkian Foundation (FCG).
Abstract (Originalsprache)
Background
The global scale-up of antiretroviral treatment (ART) offers significant health benefits by suppressing HIV-1 replication and increasing CD4 cell counts. However, incomplete viral suppression poses a potential threat for the emergence of drug resistance mutations (DRMs), limiting ART options, and increasing HIV transmission.
Objective
We investigated the patterns of transmitted drug resistance (TDR) and acquired drug resistance (ADR) among HIV-1 patients in Portugal.
Methods
Data were obtained from 1050 HIV-1 patient samples submitted for HIV drug resistance (HIVDR) testing from January 2022 to June 2023. Evaluation of DRM affecting viral susceptibility to nucleoside/tide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs) was performed using an NGS technology, the Vela Diagnostics Sentosa SQ HIV-1 Genotyping Assay.
Results
About 71% of patients were ART naïve and 29% were experienced. Overall, 20% presented with any DRM. The prevalence of TDR and ADR was 12.6% and 41.1%, respectively. M184V, T215S, and M41L mutations for NRTI, K103N for NNRTI, and M46I/L for PIs were frequent in naïve and treated patients. E138K and R263K mutations against INSTIs were more frequent in naïve than treated patients. TDR and ADR to INSTIs were 0.3% and 7%, respectively. Patients aged 50 or over (OR: 1.81, p = 0.015), originating from Portuguese-speaking African countries (PALOPs) (OR: 1.55, p = 0.050), HIV-1 subtype G (OR: 1.78, p = 0.010), and with CD4 < 200 cells/mm3 (OR: 1.70, p = 0.043) were more likely to present with DRMs, while the males (OR: 0.63, p = 0.003) with a viral load between 4.1 to 5.0 Log10 (OR: 0.55, p = 0.003) or greater than 5.0 Log10 (OR: 0.52, p < 0.001), had lower chances of presenting with DRMs.
Conclusions
We present the first evidence on TDR and ADR to INSTI regimens in followed up patients presenting for healthcare in Portugal. We observed low levels of TDR to INSTIs among ART-naïve and moderate levels in ART-exposed patients. Regimens containing PIs could be an alternative second line in patients with intermediate or high-level drug resistance, especially against second-generation INSTIs (dolutegravir, bictegravir, and cabotegravir).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Health and Tropical Medicine (GHTM), Associate Laboratory in Translation and Innovation Towards Global Health (LA-REAL), Instituto de Higiene e Medicina Tropical (IHMT), Universidade NOVA de Lisboa (UNL), Rua da…
- Centro de Investigação em Saúde de Angola (CISA), Caxito, Angola.
- Instituto Nacional de Investigação em Saúde (INIS), Luanda, Angola.
- Laboratório de Biologia Molecular, Serviço de Patologia Clínica, Unidade Local de Saúde Lisboa Ocidental, Hospital Egas Moniz, 1349-019 Lisbon, Portugal.
- Biologia Molecular, Serviço de Patologia Clínica, Centro Hospitalar de Lisboa Central, 1150-199 Lisbon, Portugal.
- Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, Caparica, 2829-511 Almada, Portugal.
ORCID-Profile: Marta Pingarilho, Fátima Gonçalves, M Rosário O Martins, Ana B Abecasis, Perpétua Gomes
Förderung
- FCT in the Scopus of INTEGRIV project
- FCT MARVEL
- Calouste Gulbenkian Foundation (FCG)
- Africa Research Excellence Fund (AREF)
- Science and Technology Development Project (PDCT)
- FCT
Zitieren
APA
Pimentel, V., Pingarilho, M., Sebastião, C. S., Miranda, M., Gonçalves, F., Cabanas, J., Costa, I., Diogo, I., Fernandes, S., Costa, O., Corte-Real, R., Martins, M. R. O., Seabra, S. G., Abecasis, A. B., & Gomes, P. (2024). Applying Next-Generation Sequencing to Track HIV-1 Drug Resistance Mutations Circulating in Portugal. Viruses. https://doi.org/10.3390/v16040622
Vancouver
Pimentel V, Pingarilho M, Sebastião CS, Miranda M, Gonçalves F, Cabanas J, et al. Applying Next-Generation Sequencing to Track HIV-1 Drug Resistance Mutations Circulating in Portugal. Viruses. 2024. doi:10.3390/v16040622
BibTeX
@article{Pimentel2024,
author = {Pimentel, Victor and Pingarilho, Marta and Sebastião, Cruz S and Miranda, Mafalda and Gonçalves, Fátima and Cabanas, Joaquim and Costa, Inês and Diogo, Isabel and Fernandes, Sandra and Costa, Olga and Corte-Real, Rita and Martins, M Rosário O and Seabra, Sofia G and Abecasis, Ana B and Gomes, Perpétua},
title = {Applying Next-Generation Sequencing to Track HIV-1 Drug Resistance Mutations Circulating in Portugal},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16040622}
}
EUVIMED